(51 days)
Not Found
Not Found
No
The device description and performance studies focus on the stability and reproducibility of a blood control material, with no mention of AI or ML algorithms for analysis or interpretation.
No
The device is a control for diagnostic tests (CBC, differential, reticulocyte, NRBC) and not used to treat or cure a disease.
No
Explanation: The device is described as a "control" for "complete blood cell count (CBC), white blood cell differential, reticulocyte and nucleated red blood cell (NRBC) parameters." Controls are used to verify the proper operation of diagnostic instruments, not to make a diagnosis themselves. Therefore, this device is a control product, not a diagnostic device.
No
The device description explicitly states it is a suspension of stabilized human and animal blood packaged in glass vials, indicating it is a physical control material, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states it's a "control for complete blood cell count (CBC), white blood cell differential, reticulocyte and nucleated red blood cell (NRBC) parameters on Sysmex XE - series instruments." Controls are used to verify the performance of in vitro diagnostic tests.
- Device Description: It's a "suspension of stabilized human and animal blood." This material is used in vitro (outside the body) to assess the accuracy and precision of the blood analysis instruments.
- Function: It's used to check the performance of instruments that perform in vitro diagnostic tests (CBC, differential, etc.).
Therefore, based on the provided information, e-CHECK (XE)™ fits the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
e-CHECK (XE)™ is intended to be used as a control for complete blood cell count (CBC), white blood cell differential, reticulocyte and nucleated red blood cell (NRBC) parameters on Sysmex XE - series instruments.
Product codes (comma separated list FDA assigned to the subject device)
JPK
Device Description
e-CHECK (XE) is a suspension of stabilized human and animal blood packaged in dlass vials, containing 4.6 mL volumes. Closures are injection molded polypropylene screw top caps. The device will consist of three levels: Low CBC/High Retic (Low Level), Normal CBC/Intermediate Retic (Normal Level), and High CBC/Low Retic (High Level).The vials are packaged in a welled vacuum formed clam-shell container with the package insert and assav sheet.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Three studies of e-CHECK (XE) were conducted: I) Lot to Lot Reproducibility and Comparison to Whole Blood; II) Long Term Stability; and III) Open Vial Stability. Study results showed e-CHECK (XE) to be consistently reproducible, substantially equivalent to the predicate products, and stable for the entire product dating.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
e-CHECK manufactured by Streck
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 864.8625 Hematology quality control mixture.
(a)
Identification. A hematology quality control mixture is a device used to ascertain the accuracy and precision of manual, semiautomated, and automated determinations of cell parameters such as white cell count (WBC), red cell count (RBC), platelet count (PLT), hemoglobin, hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC).(b)
Classification. Class II (special controls). Except when intended for use in blood components, the device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
0
510(k) Summary of Safety and Effectiveness
K0632/8
SEC 1 4 2006
| 510(k) Submitter: | Streck
7002 South 109th Street
Omaha, NE 68128 |
|-------------------------|---------------------------------------------------------------|
| Official Correspondent: | Carol Thompson
Quality Assurance Manager
(402) 537-5313 |
| Date Prepared: | December 5, 2006 |
| Names of Device: | |
| Trade Name: | e-CHECK (XE)TM |
| Common Name: | Assayed hematology control |
| Classification Name: | Hematology quality control mixture (§ 864.8625) |
| Predicate Devices: | e-CHECK manufactured by Streck |
Description:
e-CHECK (XE) is a suspension of stabilized human and animal blood packaged in dlass vials, containing 4.6 mL volumes. Closures are injection molded polypropylene screw top caps. The device will consist of three levels: Low CBC/High Retic (Low Level), Normal CBC/Intermediate Retic (Normal Level), and High CBC/Low Retic (High Level).The vials are packaged in a welled vacuum formed clam-shell container with the package insert and assav sheet.
Intended Use:
e-CHECK (XE)™ is intended to be used as a control for complete blood cell count (CBC), white blood cell differential, reticulocyte and nucleated red blood cell (NRBC) parameters on Sysmex XE - series instruments.
Comparison with Predicate Devices:
Like e-CHECK, e-CHECK (XE) is intended to enable the user to verify satisfactory performance of Sysmex XE Series hematology instruments in recovery of CBC and white cell differential parameters on whole blood specimens. Both devices contain stabilized human red blood cells, human white cells, and simulated platelets, which properly mimic human whole blood components on Sysmex analyzers.
Unlike e-CHECK, e-CHECK (XE) contains simulated human nucleated red blood cells (NRBCs). This allows the user to verify proper performance of NRBCs on the Sysmex XE - 2100. The addition to NRBC is the difference between the two products.
Discussion of Tests and Test Results:
Three studies of e-CHECK (XE) were conducted:
I) Lot to Lot Reproducibility and Comparison to Whole Blood; II) Long Term Stability; and III) Open Vial Stability. Study results showed e-CHECK (XE) to be consistently reproducible, substantially equivalent to the predicate products, and stable for the entire product dating.
Conclusions Drawn From Tests:
Study results show e-CHECK (XE) to be consistently reproducible, substantially equivalent to the predicate product, and stable for the entire product dating. e-CHECK (XE) is a safe and effective product, which fulfills its intended use when used as instructed in the product package insert.
1
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird with three stylized wing segments.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
STRECK C/O Kerrie Oetter 7002 South 109th Street Omaha, NE 68128
JEC 1 4 2006
Re: K063218
Trade/Device Name: e-CHECK Regulation Number: 21 CFR 864.8625 Regulation Name: Hematology Quality Control Mixture Regulatory Class: Class II Product Code: JPK Dated: December 5, 2006 Received: December 6, 2006
Dear Ms. Oetter:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
2
Page 2 -
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Toba R. Beckerf
Robert L. Becker, Jr., MD, PhD Director Division of Immunology and Hematology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
3
Page 3 –
cc: HFZ-401 DMC
: : : : :
:
HFZ-404 510(k) Staff HFZ- 440 Division D.O.
4
510(k) Number (if known): K063218
Device Name: e-CHECK (XE)™
Indications For Use:
e-CHECK (XE)™ is intended to be used as a control for complete blood cell count (CBC), white blood cell differential, reticulocyte and nucleated red blood cell (NRBC) parameters on Sysmex XE - series instruments.
Prescription Use X (Per 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(Please DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Josephine Bautista
Division/Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
310(k) K063218
Page 1 of __1